Back

Empaglifozin modifies the arterial stiffness in type-2 diabetic patients: a preliminary report

13 May 2024 (12:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Pharmacology and pharmacotherapy Antidiabetic Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Mauro Feola

Cardiology Department, Mondovi (Italy)

5 More presentations in this session

Presentation thumbnail
Real-life adverse events with SGLT-2 inhibitors: different safety profiles according to their indications?
Mr O. Chebbo (Montpellier, FR)
Abstract Slides Video
Presentation thumbnail
Assessing doctors' knowledge and confidence regarding SGLT2 inhibitor prescribing practices, side-effects, and ESC guidelines
Doctor E. Higgisson (Dublin, IE)
Abstract Slides Video
Presentation thumbnail
Efficacy of ARNI in patients using LVAD: a systematic review and meta-analysis
Doctor E. Hasabo (Galway, IE)
Abstract Slides Video
Presentation thumbnail
Intravenous iron therapy for patients with heart failure and iron deficiency: an updated meta-analysis of randomized controlled trials
Mr G. Yeap (GB)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of SGLT2-i in patients using LVAD: a systematic review and meta-analysis
Doctor E. Hasabo (Galway, IE)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacology and pharmacotherapy

The Event

Event poster

Heart Failure 2024

13 May 2024 12:00 CET
You may be interested in
thumbnail
Congress Session
Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
thumbnail
Congress Session
2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources